Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Arcutis Biotherapeutics, Inc. clinical trials
The registry lists 25 studies whose lead sponsor is Arcutis Biotherapeutics, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Arcutis Biotherapeutics, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Arcutis Biotherapeutics, Inc..
- Arcutis Biotherapeutics, Inc.25 studiesSame company
Something wrong?
Focus areas
Conditions Arcutis Biotherapeutics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 25 of 25.
- Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234RecruitingNCT07453602Phase 1
- Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisCompletedNCT04286607Phase 3
- Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)CompletedNCT04746911Phase 2
- Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body PsoriasisCompletedNCT07340216Phase 1
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)CompletedNCT04845620Phase 3
- Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisCompletedNCT04804605Phase 3
- Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic DermatitisCompletedNCT06998056Phase 2
- Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)CompletedNCT05028582Phase 3
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisCompletedNCT04773587Phase 3
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)CompletedNCT04773600Phase 3
- Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial VitiligoTerminatedNCT04811131Phase 2
- Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic DermatitisCompletedNCT04445987Phase 2
- Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand EczemaCompletedNCT04378569Phase 1/2
- Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)CompletedNCT04973228Phase 3
- Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)CompletedNCT04655313Phase 2
- Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate EczemaCompletedNCT04156191Phase 1
- Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic DermatitisCompletedNCT04091646Phase 2
- Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03916081Phase 2
- Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisCompletedNCT04211389Phase 3
- Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisCompletedNCT04211363Phase 3
- Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body PsoriasisCompletedNCT04128007Phase 2
- The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque PsoriasisCompletedNCT03638258Phase 2
- Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque PsoriasisCompletedNCT03764475Phase 2
- Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque PsoriasisCompletedNCT03392168Phase 1/2
- Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque PsoriasisCompletedNCT04279119Phase 1